The Rosen Law Firm announces that it is investigating potential
securities claims against Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
On November 6, 2014, Salix Pharmaceuticals announced lower than expected
third-quarter earnings and sales forecasts, as well as the sudden
resignation of its Chief Financial Officer, Adam Derbyshire. In a
conference call with analysts that same day, Chief Executive Officer,
Carolyn Logan, disclosed that the Audit Committee is probing the
Company’s statements concerning its inventory levels. On this news,
shares of Salix Pharmaceuticals fell sharply during intraday trading on
November 7, 2014, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Salix Pharmaceuticals shareholders as a result of this
adverse information. If you purchased Salix Pharmaceuticals stock on or
before November 6, 2014 and wish to join the class action, please visit
the website at http://rosenlegal.com/cases-431.html
for more information. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Copyright Business Wire 2014